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THE ETHICS OF MEDICARE POLICY: INCREASING
TRANSPLANT ACCESS AND SURVIVAL
Elisa J. Gordon*
"Tis not enough to help the feeble up, But to support him after."'
Inspired by the Institute of Medicine (1OM) Reports-Crossing the
Quality Chasm2 and Leadership by Example3-the American health-
care system is undergoing careful scrutiny of the quality of care that it
provides. "Quality" refers to "the degree to which health services for
individuals and populations increase the likelihood of desired health
outcomes and are consistent with current professional knowledge." 4
Problems with quality of care occur when patients do not obtain bene-
ficial health services (underuse), undergo treatments from which they
do not benefit (overuse), and receive medical services but those ser-
vices are provided poorly (misuse). 5 Although the likelihood of at-
taining better health outcomes increases with better quality of care,
other factors can intervene to undermine this relationship such that
quality must be assessed by examining processes and outcomes of
care.6 Policymakers, health professionals, and scholars are therefore
paying greater attention to the outcomes of treatments and interven-
* Ph.D., M.P.H., Assistant Professor of Bioethics and Health Policy, Neiswanger Institute for
Bioethics and Health Policy, Loyola University of Chicago, Department of Medicine, Bldg. 120,
Rm. 280, 2160 South First Avenue, Maywood, IL 60153; Tel: 708-327-9220; Fax: 708-327-9209;
egordol@Lumc.edu. I would like to express my gratitude to Thomas Prohaska, Ross Mullner,
and Ash Sehgal for their insightful comments on earlier drafts of this Article. I also thank the
faculty at the Department of Nephrology at Loyola University of Chicago for their helpful feed-
back on an earlier presentation. I am grateful to Christine Matott of the DePaul Law Review
Editorial Board for her editorial assistance in the revision and publication of this work. Sup-
ported by grant DK063953 from the National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD.
1. WILLIAM SHAKESPEARE, TIMON OF ATHENS act 1, sc. 1, lines 107-08.
2. COMM. ON QUALITY OF HEALTHCARE, INST. OF MED., CROSSING THE QUALITY CHASM: A
NEW HEALTH SYSTEM FOR THE 21ST CENTURY (2001).
3. LEADERSHIP BY EXAMPLE: COORDINATING GOVERNMENT ROLES IN IMPROVING HEALTH
CARE QUALITY (Janet M. Corrigan et al. eds., 2003).
4. MEDICARE: A STRATEGY FOR QUALITY ASSURANCE 21 (Kathleen N. Lohr ed., 1990) (em-
phasis omitted).
5. Mark R. Chassin et al., The Urgent Need to Improve Health Care Quality, 280 JAMA 1000
(1998).
6. Id.
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tions in an effort to reduce the burden of illness, injury, and disability,
and to improve the health of the people of the United States. 7
In the field of kidney transplantation, there is a relatively small but
growing awareness of the need to focus on quality outcomes-specifi-
cally, long-term graft survival and quality of life. While short-term
acute rejection has come under control, long-term graft survival re-
mains inadequate. 8 Short-term acute rejection occurs within one year
of kidney receipt; concerns about long-term graft survival pertain to
the period beyond one-year posttransplant. The number of kidneys
lost is substantial and increases over time. As one transplant physi-
cian stated, "The complications of life-long immunosuppression now
replace rejection as one of the major obstacles to long-term graft and
patient survival."9 Accordingly, economic concerns have shifted away
from the transplant procedure to patient management and mainte-
nance immunosuppression.10
But these efforts have paid little attention to the broader political,
economic, and social contexts in which patients live and manage their
kidney transplants in the long-term. Taking an ecological approach11
to assuring quality transplant outcomes requires that we consider such
broader social factors. This Article focuses primarily on one such fac-
tor: the Medicare policy financing immunosuppression.
Over the last decade, the Medicare policies that finance kidney
transplantation have undergone a series of modifications. Since 1972,
when legislation funding renal replacement therapy for end-stage re-
nal disease (ESRD) was enacted,12 entitlements have progressively
expanded from covering solely the transplant operation and associ-
ated physician fees to now covering eighty percent of the costs of post-
transplant immunosuppressant medications for three years. 13 More
7. RICHARD A. RETTIG AND NORMAN G. LEVINSKY, KIDNEY FAILURE AND THE FEDERAL
GOVERNMENT 330 (1991).
8. Cohm C. Magee & Manuel Pascual, Update in Renal Transplantation, 164 ARCHIVES INTER-
NAL MED. 1373 (2004).
9. Ross B. Isaacs, Optimal Transplant Immunosuppression: A Case of the Haves and Have
Nots?, 37 AM. J. KIDNEY DISEASES 160 (2001).
10. Kevin J. Gorman, Evaluating Strategies for Reducing the Costs of Immunosuppression, 5
LIVER TRANSPLANTATION & SURGERY S115 (1999).
11. James F. Sallis & Neville Owen, Ecological Models of Health Behavior, in HEALTH BE-
HAVIOR AND HEALTH EDUCATION: THEORY, RESEARCH, AND PRACTICE 462 (Karen Glanz et al.
eds., 3d. ed. 2002).
12. See Social Security Amendments of 1972, Pub. L. No. 92-603, § 2991, 86 Stat. 1329 (1972).
13. Medicare provided eighty percent of the cost of immunosuppressive medications for one
year posttransplant in 1986; between 1993 and 1995, coverage was extended to three years. Rob-
ert S. Woodward et al., Effect of Extended Coverage of Immunosuppressive Medications by
Medicare on the Survival of Cadaveric Renal Transplants, 1 AM. J. TRANSPLANTATION 69, 69-73
(2001); see also Memorandum from Director-Office Program Operations Procedures, BPO, to
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recently, the 109th Congress considered Bill S.173, the Comprehen-
sive Immunosuppressive Drug Coverage for Transplant Patients Act
of 2005, which is designed to expand coverage for Medicare benefi-
ciaries for the life of the kidney. This trajectory of incrementally in-
creasing Medicare coverage of immunosuppression for kidney
transplant recipients is noteworthy because it reflects policymakers'
recognition of the vital role of immunosuppression in the survival of
kidney transplant grafts. It also signifies policymakers' efforts to assist
kidney recipients facing financial hardship caused by the high costs of
immunosuppressive medications. Medicare's increasing coverage of
immunosuppression is certainly beneficial to kidney transplant recipi-
ents. The current health policy, however, still undermines efforts to
improve long-term quality care.
In this Article I explain that the current Medicare policy is insuffi-
cient because it generates problems relating to quality in terms of bar-
riers to access and cost. I argue that the current policy presents
negative ramifications for kidney graft survival and patient quality of
life (QOL). Specifically, kidney recipients' inability to afford medica-
tions after the three-year mark (not to mention the twenty percent of
costs patients must pay out of pocket during the initial three years)
places kidneys at risk of rejection. Kidney grafts lost accordingly re-
turn patients to dialysis, thereby creating an even greater demand for
kidney transplants and further burdening society with greater costs.
Ironically, it is the improvements in patient survival and QOL that
make kidney transplantation the treatment of choice in the first
place.14 Yet, the limitations of the Medicare policy undermine the
very goals that transplantation has set out to achieve.
I propose a new framework for considering the goals of the kidney
transplant endeavor. Instead of focusing on the receipt of the trans-
Associate Regional Administrators for Medicare (Dec. 7, 1994) (available at http://
www.transweb.org/reference/articles/hrd.html). Policymakers and physicians recall that trans-
plant recipients' entitlement to immunosuppressants was limited to three years because origi-
nally physicians thought that immunosuppression would not be required indefinitely but could
be stopped after the patient became stable after six to twelve months. E-mail from John Sadler,
President and CEO of IDF Parkview Dialysis Center, to Elisa Gordon, Assistant Professor of
Bioethics and Health Policy, Loyola University of Chicago (Sept. 19, 2005, 15:54 CST) (on file
with author). As the coverage of immunosuppressants expanded from one to three years, the
decision was based on making coverage coincide with entitlement. E-mail from Paul Eggers,
Program Director for Kidney and Urology Epidemiology, National Institutes of Diabetes and
Digestive and Kidney Diseases, to Elisa Gordon, Assistant Professor of Bioethics and Health
Policy, Loyola University of Chicago (Sept. 19, 2005) (on file with author).
14. See Andreas Laupacis et al., A Study of the Quality of Life and Cost-Utility of Renal Trans-
plantation, 50 KIDNEY INT'L 235 (1996); Robert A. Wolfe et al., Comparison of Mortality in All
Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Ca-
daveric Transplant, 341 NEW ENG. J. MED. 1725 (1999).
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plant as the end goal (with increasing organ donation as the interme-
diate goal), we must extend our focus and goal to long-term transplant
outcomes. I propose that we must accordingly revise Medicare policy
by extending coverage to all kidney recipients for the life of the kid-
ney. This extended coverage will promote long-term survival of kid-
ney grafts and ensure that kidney transplantation remains cost-
effective and worthwhile. This will help reduce costs to the public and
will reduce the demand for kidney transplants by preventing prema-
ture rejection of kidneys due to limited access to immunosuppressive
medications.
II. EPIDEMIOLOGICAL CONTEXT OF ESRD
In order to understand fully the magnitude of the impact and signif-
icance of the current Medicare policy on immunosuppressive medica-
tion coverage, it is important first to appreciate the epidemiological
context of ESRD and the kidney transplant population. In 2002, there
were over 431,000 patients with ESRD in the United States requiring
some form of renal replacement therapy.' 5 In that same year, the
ESRD incidence rate was 333 per million population (pmp) while the
prevalence was about 1,435 patients pmp.1 6 The rate of increase of
incidence has slowed since 2000 to 1.4% per year, while the preva-
lence rate increased by 2.5% from 2001 to 2002.17 The projected pop-
ulation growth over the next thirty years, especially among the
elderly, minority, and diabetic populations, means that there will be
increased demand for renal replacement therapy. 18 By 2030, the num-
ber of patients with ESRD is estimated to be 2.24 million, a five-fold
increase. 19
Presently, there are just over 65,903 candidates waiting for a kidney
transplant. 20 There was a 10.5% increase in the number of candidates
waiting for a kidney transplant between 2002 and 2003, from 51,236 to
56,618.21 There was, however, only a 2.1% increase between 2002 and
2003 in the number of kidney transplants performed (from 15,707 to
16,043-a 3.7% increase for living donors and a 7.6% decrease for
15. U.S. RENAL DATA SYSTEM, 2004 ANNUAL DATA REPORT: ATLAS OF END-STAGE RENAL
DISEASE IN THE UNITED STATES 319 tbl.b.1 (2004) [hereinafter 2004 ANNUAL REPORT].
16. Id. at 60, 64.
17. Id. at 60.
18. U.S. RENAL DATA SYSTEM, 2003 ANNUAL DATA REPORT: ATLAS OF END-STAGE RENAL
DISEASE IN THE UNITED STATES 54 (2003).
19. Id. at 55.
20. Organ Procurement & Transplantation Network, Data, http://www.optn.org/data/ (last vis-
ited Mar. 27, 2006).
21. Id.
1048 [Vol. 55:1045
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living donors).22 The fact that the growth in candidates continues to
be higher than the rate of transplantation exacerbates the scarce con-
dition of kidneys for transplantation.
As previously noted, long-term graft survival remains inadequate.
Specifically, the rate of kidney graft survival diminishes over time.
TABLE 1
UNADJUSTED GRAFT SURVIVAL AT 1 YEAR, 3 YEARS, 5 YEARS,
AND 10 YEARS
2 3
Living Related
Cadaveric Donor Total
N % N % N %
Survival at 1 year 16,023 88.7% 11,423 94.3% 27,446 91.0%
(2000-2001)
# Kidneys Lost 2,041 11.3% 690 5.7% 2,731 9.0%
Survival at 3 years 15,799 78.4% 9,060 87.7% 24,859 81.6%
(1998-1999)
# Kidneys Lost 4,353 21.6% 1,271 12.3% 5,624 18.4%
Survival at 5 years 15,224 65.7% 7,578 78.6% 22,802 69.5%
(1996-1997)
# Kidneys Lost 7,948 34.3% 2,063 21.4% 10,011 30.5%
Survival at 10 14,372 36.4% 4,928 55.2% 19,300 39.9%
years (1991-1992)
# Kidneys Lost 25,112 63.6% 4,000 44.8% 29,112 60.1%
To illustrate, the three-year, five-year, and ten-year survival rates are
81.6%, 69.5%, and 39.9%, respectively, among all kidney recipients in
the United States. 24 Thus, after three years, five years, and ten years,
5,624, 10,011, and 29,112 kidneys are lost, respectively. It is important
to point out that the rate of kidney loss increases over time. Such high
rates of graft loss and their cause warrant greater attention.
22. Id.
23. 2003 OPTN/SRTR ANNUAL REPORT 1993-2002. The publication supplying the data from
the table provides the following disclaimer: "The data and analysis reported in the 2003 Annual
Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry
of Transplant Recipients have been supplied by UNOS and URREA under contract wth HT--S.
The authors alone are responsible for reporting and interpreting these data." Id.
24. U.S. ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK AND THE SCIENTIFIC
REGISTRY OF TRANSPLANT RECIPIENTS, 2003 ANNUAL REPORT (2003). The rate of kidney loss
increases over time as follows: from one to three years (nine percent are lost), from three to five
years (twelve percent are lost), and from five to ten years (thirty percent are lost). This reflects
an increase in rate from three percent to eighteen percent. The first two transition points occur
over a two-year period. Even though these survival rates are established every two years for the
first two points in time, and the last point in time is taken after five years, a more accurate rate of
graft loss would require a data from a seven-year point in time.
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The main causes of graft loss after the first year posttransplant are
patient death and chronic allograft nephropathy (CAN). 25 CAN re-
fers to the "progressive decline of renal function seen in some renal
transplant recipients in association with alloantigen-dependent and al-
loantigen-independent factors. '26 Prevalence rates of CAN vary from
eighty-one percent to eighty-six percent.27 Physicians have therefore
proposed that attention be directed toward the prevention of CAN. 28
To understand graft loss and CAN, it is imperative to appreciate the
broader context of patients' ability to obtain immunosuppression by
turning our attention to issues of access and cost presented by Medi-
care's entitlement policy.
III. ACCESS TO MEDICAL CARE
It is well established that access to medical care affects health out-
comes.29 Gaining access to immunosuppressive medication is funda-
mentally important because kidney transplant recipients need it for
their kidney graft to function. Access can be defined as "[t]hose
dimensions which describe the potential and actual entry of a given
population group to the health care delivery system."'30 Traditionally,
research on access has examined factors influencing the (non)use of
services, including the availability of insurance coverage, physical or
geographic access to healthcare services, demographic characteristics
of individuals potentially seeking healthcare services, and cultural fac-
tors that may explicitly or subtly affect use of healthcare services and
communication with healthcare professionals.31 A more recent con-
ceptualization of access, proposed by the 10M, has shifted focus onto
the service itself and its effects-namely, the outcomes, effectiveness,
and cost of using the services. 32 The IOM's approach is directly appli-
25. Rahul M. Jindal & Sundaram Hariharan, Chronic Rejection in Kidney Transplants: An In-
Depth Review, 83 NEPHRON 13 (1999); Magee & Pascual, supra note 8.
26. Miguel A. Vazquez, Chronic Rejection of Renal Transplants: New Clinical Insights, 320
AM. J. MED. Sci. 43 (2000).
27. Ziad A. Massy et al., Chronic Renal Allograft Rejection: Immunologic and Nonimmuno-
logic Risk Factors, 49 KIDNEY INT'L 518 (1996); K. Venkateswara Rao & John K. Rose, Inci-
dence, Histological Pattern, and Clinical Outcome of Rejection Episodes Occurring in the Late
Posttransplant Period, 40 TRANSPLANTATION 631 (1985).
28. See Sundaram Hariharan, Long-Term Kidney Transplant Survival, 38 AM. J. KIDNEY Dis-
EASES S44 (2001); Magee & Pascual, supra note 8.
29. Norman Daniels et al., Why Justice Is Good for Our Health: The Social Determinants of
Health Inequalities, 128 DAEDALUS 215 (1999); Adam Wagstaff, Poverty and Health Sector Ine-
qualities, 80 BULL. WORLD HEALTH ORG. 97 (2002).
30. Lu Ann Aday & Ronald M. Andersen, Equity of Access to Medical Care: A Conceptual
and Empirical Overview, 19 MED. CARE 4, 5-6 (1981).
31. Id.
32. ACCESS TO HEALTH CARE IN AMERICA (Michael Millman ed., 1993).
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cable to kidney transplantation because attaining immunosuppressive
medications directly affects kidney graft survival, as discussed below.
Since the IOM report, Marsha Gold has proposed another framework
for access that encompasses factors pertaining to the impact of man-
aged care on financing and delivering the healthcare systems and
processes. 33 Gold's framework is relevant to the kidney transplant re-
cipients who rely on private insurance (and thus managed care) in ad-
dition to Medicare. Her framework, however, does not apply to the
majority of transplant recipients who rely on Medicare only, because
ESRD patients are legally barred from enrolling in Medicare-man-
aged-care plans which are designed to enhance quality care.34
Concerns about access raise questions about justice in terms of eq-
uity. Equity commonly refers to equal utilization of healthcare re-
sources for equal need.35 Distributing services on the basis of people's
need for them36 constitutes a form of fairness based on egalitarian
notions of social justice. Access to healthcare resources can also be
said to be equitable when the distribution of health resources and in-
dividual background characteristics-health insurance, ethnicity, and
income-have no effect on differences in utilization of healthcare re-
sources. 37 According to a 1983 report by a presidential commission
studying inequality in healthcare, access is deemed ethical when "eve-
ryone has access to adequate care without being subject to excessive
burdens." 38
When using the IOM framework of access to medical care, there are
several goals related to equity of access. Only one goal, however, is
pertinent to the current Medicare policy on immunosuppression cov-
erage. Specifically, when the goal is to provide equality of opportu-
nity, the criterion of equity becomes conceptualized as similar
treatment based predominantly on need (either perceived or evalu-
ated), as well as predisposing characteristics of the population (age,
sex, race, education) and enabling factors (income, regular source, in-
33. Marsha Gold, Beyond Coverage and Supply: Measuring Access to Healthcare in Today's
Market, 33 HEALTH SERV. RES. 625, 625-52 (1998).
34. Caitlin Carroll Oppenheimer et al., Evaluation of the ESRD Managed Care Demonstration
Operuiiuns, 24 HLALI h CARE FINANCING REV. 7, 7 (2003); Press Release, Ctrs. for Medicare &
Medicaid Servs., Managed Care Plan Offered to Medicare Beneficiaries in Chicago and Illinois
Suburbs (Nov. 18, 2004), http://www.cms.hhs.gov/media/press/release.asp?Counter=1264.
35. Gavin Mooney, What Does Equity in Health Mean?, 40 WORLD HEALTH STAT. Q. 296
(1987).
36. Aday & Andersen, supra note 30, at 6.
37. AccEss TO HEALTH CARE IN AMERICA, supra note 32.
38. PRESIDENT'S COMM'N FOR THE STUDY OF ETHICAL PROBLEMS IN MED. & BIOMEDICAL &
BEHAv. RESEARCH, SECURING ACCESS TO HEALTH CARE: THE ETHICAL IMPLICATIONS OF DIF-
FERENCES IN THE AVAILABILITY OF HEALTH SERVICES 22 (1983).
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surance). 39 The indicators of equitable access include regular source
of care and insurance coverage. 40
The concept of "need" is a highly debated term for which there are
different approaches to measurement. 41 A traditional, clinical-ori-
ented approach considers need as the state of pretreatment health.42
Accordingly, those with worse health have greater need for treatment.
This approach does not apply to ESRD because dialysis is available as
an alternative renal replacement therapy to transplantation. (As an
exception, patients with poorly functioning circulatory systems have
greater need for transplantation, which for them is lifesaving). Thus,
"need" (at least for adults) does not factor into the point system in
kidney allocation.
Alternatively, a health-economic approach construes need as an in-
dividual's capacity to benefit from healthcare. 43 This approach con-
siders the amount of healthcare resources necessary to address ill
health. This approach is directly applicable to the case of kidney
transplantation because all kidney transplant recipients need immu-
nosuppressant medications for their transplanted kidney graft to func-
tion. As such, kidney graft survival depends upon recipients'
attainment of immunosuppression. Yet, as discussed below, not eve-
ryone has the same capacity to obtain immunosuppressant medica-
tions. Because all ESRD patients are entitled to renal replacement
therapy, and immunosuppression constitutes a part of transplantation
as one type of renal replacement therapy, equity means that there
should be parity in the regular attainment of immunosuppression and
insurance coverage for it. Let us consider how the issue of equitable
access to medications relates to kidney transplant recipients and their
graft survival.
Access to health insurance is especially salient for kidney transplant
recipients in their ability to obtain their immunosuppressant medica-
tions. Kidney transplant recipients must take immunosuppressive
medications for as long as their kidney graft works so as to prevent
kidney rejection. Based on Medicare policy, patients (who are not
disabled or age sixty-five and older) are responsible for covering
twenty percent of the costs of immunosuppressive medications for
39. Gold, supra note 33.
40. Id.
41. Adam Oliver & Elias Mossialos, Equity of Access to Health Care: Outlining the Founda-
tions for Action, 58 J. EPIDEMIOLOGY COMM. HEALTH 655 (2004).
42. Id.
43. Id.
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three years and the full costs thereafter. Copayments for immunosup-
pression amount to approximately $167-$233 per month.44
Furthermore, kidney recipients commonly take multiple medica-
tions to manage a host of comorbidities such as hypertension,
diabetes, and psychological problems.45 Affording both immuno-
suppressants and medications for underlying comorbidities may pre-
sent an even greater financial challenge, especially for those lacking
secondary insurance. The finding that hemodialysis patients who have
a greater number of secondary insurance carriers are prescribed more
medications for comorbidities 46 could very well also apply to kidney
transplant recipients. The inability to obtain sufficient medications
would result in poorly managed comorbidities, which may then exac-
erbate patients' chronic kidney disease, the condition of the trans-
planted kidney graft, or both. To date, no studies have documented
this association.
IV. DISPARITIES IN INSURANCE COVERAGE
Insurance coverage among kidney recipients varies greatly and re-
sults in an unequal ability to gain access to medications, and thus
raises concerns about graft survival equity. A review of data from the
United Network on Organ Sharing (UNOS) on 9,398 cadaveric renal
transplants revealed the following types of patient insurance coverage:
sixty-eight percent Medicare, twenty-five percent private insurance,
and five percent Medicaid.47 In addition, over twelve percent of the
ESRD population are not eligible for Medicare and rely on Medicaid
instead.48 Eligibility remains an issue for the Medicaid-only popula-
tion.49 There are also sizable racial and ethnic differences in insurance
coverage. For example, in one study, thirty-one percent of whites
44. Bertram L. Kasiske et al., Payment for lmmunosuppression After Organ Transplantation,
283 JAMA 2445 (2000).
45. Arthur J. Matas et al., Life Satisfaction and Adverse Effects in Renal Transplant Recipients:
A Longitudinal Analysis, 16 CLINICAL TRANSPLANTATION 113 (2002).
46. Ya-chen Tina Shih, Effect of Insurance on Prescription Drug Use by ESRD Beneficiaries,
20 HEALTH CARE FINANCING REV. 39. 48-49 (1999).
47. YONG WON CHO ET AL., NEW VARIABLES REPORTED TO THE UNOS REGISTRY AND
THEIR IMPACT ON CADAVERIC RENAL TRANSPLANT OUTCOMES-A PRELIMINARY STUDY (J.M.
Cecka & Paul I. Terasaki eds., 1995). In an effort to contain costs to HCFA from the ESRD
program, the Balanced Budget Act of 1997 mandated that private insurers cover the first thirty
months of ESRD costs for their enrollees; Medicare will be the secondary insurance payor in
these cases. Medicare Program, 64 Fed. Reg. 42,766 (Aug. 5, 1999).
48. Mae Thamer et al., Unequal Access to Cadaveric Kidney Transplantation in California
Based on Insurance Status, 34 HEALTH SERV. RES. 879 (1999).
49. Id. at 886.
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compared to sixteen percent of blacks had private insurance. 50 While
this suggests inequity in access, it remains to be determined whether
patients with private insurance have disproportionate access to immu-
nosuppressant medications.
Immunosuppressive medications are expensive, even for patients
with adequate health insurance.51 Without insurance, patients pay full
cost for the drugs. Patients may also incur other costs in follow-up
care.52 Most patients in one study perceived their health insurance to
be inadequate because they were unable to afford the medications,
the high copayment or deductible, and the cost of insurance.53
Many kidney recipients face tremendous difficulty finding suffi-
ciently paying jobs and employment with insurance benefits. Reports
have found that up to eighty-three percent of kidney transplant recipi-
ents are unemployed.54 Various factors deterring patients from em-
ployment have been identified in the transplant literature, including
the inability to find jobs with insurance coverage and having inade-
quate knowledge and skills necessary to obtain jobs, particularly those
jobs that provide insurance coverage. 55 ESRD patients tend to have
lower levels of education, income, or both when compared to the gen-
eral population.5 6 Additional barriers to employment that have been
identified include employer discrimination based on health status and
loss of disability income. 57 But no studies have as yet conclusively
confirmed these barriers.58
50. CHO ET AL., supra note 47, at 406.
51. Bertram L. Kasiske et al., A Meta-Analysis of Immunosuppression Withdrawal Trials in
Renal Transplantation, 11 J. Am. Soc', NEPHROLOGY 1910 (2000).
52. Id.
53. Mariana S. Markell et al., Unemployment in Inner-City Renal Transplant Recipients: Pre-
dictive and Sociodemographic Factors, 29 AM. J. KIDNEY DISEASES 881 (1997).
54. Id.; see also Diane L. Manninen et al., Work Disability, Functional Limitations, and the
Health Status of Kidney Transplantation Recipients Post Transplant, 5 CLINICAL TRANSPLANTA-
TION 193 (1991); Fax from United Network for Organ Sharing, to Elisa J. Gordon (May 26, 1998)
(giving the employment status two years after a graft and basing such data on the OPTN/Scien-
tific Registry data); Freda Wilkins et al., The Impact of Patient Education and Psychosocial Sup-
ports on Return to Normalcy 36 Months Post-Kidney Transplant, 17 CLINICAL
TRANSPLANTATION 78 (2003); U.S. RENAL DATA SYSTEM, 1997 ANNUAL DATA REPORT (1997)
[hereinafter 1997 ANNUAL DATA REPORT].
55. Joyce M. Carter et al., A Center-Based Approach to a Transplant Employment Program, 10
PROG. TRANSPLANTATION 204 (2000).
56. Richard A. Rettig & John H. Sadler, Measuring and Improving the Health Status of End
Stage Renal Disease Patients, 18 HEALTH CARE FINANCING REV. 77, 77 (1997); Shih, supra note
46, at 46; U.S. CENSUS BUREAU, 2000 U.S. CENSUS tbl.DP-1, available at http://cen-
stats.census.gov/dataUS/01000.pdf (last visited Nov. 23, 2004) (illustrating the profile of General
Demographic Characteristics).
57. Carter et al., supra note 55; see also Markell et al., supra note 53.
58. Carter et al., supra note 55.
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Health problems present yet another barrier to employment. In a
follow-up survey study of kidney recipients' employment status after
2.5-3.5 years posttransplant (n=226), 42.5% were unable to work due
to their health status.59 Having comorbidities can exacerbate the
problem: diabetic kidney recipients were significantly less able to
work than nondiabetic kidney recipients (74.4% vs. 34.7%).60 A ma-
jor problem exists for those who are not physically well enough to
work yet do not qualify for disability. Section 113 of the Beneficiary
Improvement and Protection Act of 2000 extended immunosuppres-
sive coverage for the life of the kidney, but only for patients who qual-
ified for Medicare coverage because of age or disability. But there is a
Catch-22: ESRD patients are typically no longer considered disabled
following kidney transplantation because transplantation is consid-
ered rehabilitation, enabling patients to return to work. In addition,
most kidney recipients do not have legally defined disabilities. Never-
theless, many kidney recipients experience a host of symptoms and
physical limitations that restrict the kind and amount of work they can
do-using eyes to read or inspect things, using fingers to grasp, and
lifting or carrying weights. 61 This disproportionate coverage (based
on disability) calls into question the meaning of entitlement or equity
in treatment regardless of financial capacity. 62
To compensate for limited financial support, kidney recipients may
engage in unregulated, potentially harmful, or illegal strategies to ob-
tain their immunosuppressants. These activities may either compro-
mise or improve graft outcomes. For instance, anthropological
research has found that kidney recipients may share medications with
other patients or work "under the table" to increase income. 63 In ad-
dition, when money is unavailable, patients have been reported to
"stretch" their medications by taking less than needed to make them
last longer, 64 or simply not to purchase them. Still other patients have
been reported to obtain unused, returned immunosuppressants (fol-
lowing dose changes) from transplant professionals. 65 Patients may
also admit themselves to the hospital emergency room for the purpose
59. Manninen et al., supra note 54, at 194.
60 d at 200.
61. Id. at 196-97.
62. RErrIG & LEVINSKY, supra note 7, at 330.
63. See also Markell et al., supra note 53, at 885; Lesley A. Sharp, Organ Transplantation as a
Transformative Experience: Anthropological Insights Into the Restructuring of the Self, 9 MED.
ANTHROPOLOGY 0. 357 (1995).
64. Elisa J. Gordon et al., Can Focusing on Self-Care Reduce Disparities in Kidney Transplan-
tation Outcomes?, 45 AM. J. KIDNEY DISEASES 935 (2005); Michelle Smith, Patients Must Be Free
of the Worry of Paying for Medications, 31 NEPHROLOGY NURSING J. 221, 222 (2004).
65. Gordon et al., supra note 64.
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of receiving free immunosuppressants. 66 While an emergency room
visit is an effective way for individuals to obtain these medications, it
is certainly not efficient as it increases healthcare costs to hospitals
and society in general. These strategies are not unusual; other kinds
of Medicare beneficiaries engage in them when Medicare does not
cover the costs of prescribed medications. 67
Medicare coverage of immunosuppressants and patients' financial
wherewithal to purchase their medications can impact whether pa-
tients even receive a transplant. Transplant professionals at one aca-
demic hospital will perform the kidney transplant operation (as long
as Medicare is obtained), regardless of whether kidney transplant can-
didates have established in advance a plan to pay for their antirejec-
tion medications. 68  In contrast, when Medicare coverage for
immunosuppressants lasted only one year, there were anecdotal re-
ports that transplant surgeons would advise patients against transplan-
tation if they could not pay for the medications needed thereafter.69
Similarly, in countries such as Mexico, transplant physicians will not
perform the operation if no certain posttransplant financial coverage
is available. 70
V. IMPACT OF INCOME AND INSURANCE COVERAGE ON KIDNEY
GRAFT SURVIVAL
Financial constraints can adversely affect patients' ability to afford
immunosuppressant medications and thus to maintain kidney trans-
plant survival and quality of life. For example, Medicaid patients have
lower graft survival than patients with private insurance. 7' In addi-
tion, low-income patients are more likely to experience allograft fail-
ure after one and five years of graft function than patients with an
adequate income.72 While graft failure after five years is a policy is-
sue, graft failure after one year is rather a matter of income and insur-
ance coverage. Moreover, numerous studies have found that the high
66. Smith, supra note 64, at 222.
67. Chien-Wen Tseng et al., Cost-Lowering Strategies Used by Medicare Beneficiaries Who
Exceed Drug Benefit Caps and Have a Gap in Drug Coverage, 292 JAMA 952, 956 (2004).
68. Elisa J. Gordon, Preventing Waste: A Ritual Analysis of Candidate Selection for Kidney
Transplantation, 7 ANTHROPOLOGY & MED. 351, 361 (2000).
69. RE~rric & LEVINSKY, supra note 7, at 172.
70. Megan Crowley-Metoka, Desperately Seeking 'Normal': The Promise and Perils of Living
With Kidney Transplantation, 61 Soc. Scl. & MED. 821 (2005).
71. CHO ET AL., supra note 47.
72. Roberto S.N. Kalil et al., Patients With a Low Income Have Reduced Renal Allograft Sur-
vival, 20 AM. J. KIDNEY DISEASES 63 (1992).
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costs of immunosuppressive medications and limited insurance cover-
age result in noncompliance. 73
Adherence or compliance with immunosuppressant directives is es-
sential for the survival of transplanted kidney grafts. Nonadherence is
the third leading cause of renal graft loss after simple allograft rejec-
tion and systemic infection. 74 Nonadherence with immunosuppres-
sant directives has serious, adverse effects on transplant outcome,
including graft loss, rejection episodes, and consequent resumption of
dialysis. 75 Similarly, studies of withdrawing or tapering of immu-
nosuppressive agents due to financial strain have been shown to result
in excessive rejection rates, graft loss, and patient death.76 Transplant
nonadherence is common, ranging from five percent to more than
forty-five percent.77
Studies examining the sociodemographic and socioeconomic factors
associated with nonadherence show that ethnicity, race, and socioeco-
nomic status play a significant role, thereby indicating disparities in
adherence rates. While myriad studies report that African Americans
and Hispanic Americans are significantly more likely to be nonadher-
ent than European Americans,78 other studies found no relationship
73. Marie A. Chisholm et al., Renal Transplant Patient Compliance With Free Immunosuppres-
sive Medications, 70 TRANSPLANTATION 1240 (2000); Doreen Papajcik et al., A Tool to Identify
Risk Factors for Noncompliance in the Adult Renal Transplant Recipient, 31 TRANSPLANTATION
PROC. 84S (1999); Daniel A. Shoskes et al., Patient Death or Renal Graft Loss Within 3 yr of
Transplantation in a County Hospital: Importance of Poor Initial Graft Function, 11 CLINICAL
TRANSPLANTATION 618 (1997); Bonita R. Siegal & Stuart M. Greenstein, Differences Between
Compliers and Partial Compliers: A Multicenter Study, 30 TRANSPLANTATION PROC. 1310 (1998).
74. Ralph H. Didlake et al., Patient Noncompliance: A Major Cause of Late Graft Failure in
Cyclosporine-Treated Renal Transplants, 20 TRANSPLANTATION PROC. 63 (1988).
75. Bonita R. Siegal & Stuart M. Greenstein, Compliance and Noncompliance in Kidney
Transplant Patients: Cues for Transplant Coordinators, 9 J. TRANSPLANTATION COORDINATION
104 (1999).
76. Vivekanand Jha et al., Impact of Cyclosporine Withdrawal on Living Related Renal Trans-
plants, 37 Am. J. KIDNEY DISEASES 119 (2001); Kasiske et al., supra note 51; Charles E. Sanders
et al., Tapering or Discontinuing Cyclosporine for Financial Reasons, 21 AM. J. KIDNEY DIS-
EASES 9-15 (1993).
77. Several studies have found noncompliance rates between five and forty-five percent.
Didlake et al., supra note 74; Patricia A. Frazier et al., Correlates of Noncompliance Among
Renal Transplant Recipients, 8 CLINICAL TRANSPLANTATION 550, 553 (1994); Papajcik et al.,
supra note 73: Laurie A. Rudman et al., Mishandling the Gift -f t ife. Noco-piance P ...I
Transplant Patients, 29 J. APPLIED SOC. PSYCHOL. 834 (1999); Robert T. Schweizer et al., Non-
compliance in Organ Transplant Recipients, 49 TRANSPLANTATION 374 (1990); Shoskes et al.,
supra note 73, at 620; Siegal & Greenstein, supra note 75.
78. See, e.g., Donald E, Butkus et al., Racial Differences in the Survival of Cadaveric Renal
Allografts: Overriding Effects of HLA Matching and Socioeconomic Factors, 327 NEW ENG. J.
MED. 840 (1992); D.J. Kiley et al., A Study of Treatment Compliance Following Kidney Trans-
plantation, 55 TRANSPLANTATION 51 (1993); Mary Rovelli et al., Noncompliance in Renal Trans-
plant Recipients: Evaluation by Socioeconomic Groups, 21 TRANSPLANTATION PROC. 379 (1989);
Siegal & Greenstein, supra note 75.
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after controlling for socioeconomic status. 79 Because minorities and
lower income kidney recipients are more likely to be nonadherent,
they are more likely to have disproportionately shorter graft survival
rates than the majority population and higher income recipients.
The fact that African Americans were 1.7 times more likely than
European Americans to suffer graft failure from a living related dona-
tion over nine years after controlling for immunologic factors (e.g.,
human leukocyte antigen matching, warm ischemic time) suggests that
socioeconomic or behavioral factors may contribute to racial and eth-
nic disparities in outcomes.8 0 Therefore, not only can financial con-
straints directly lower graft survival, but they can also generate
disparities in graft survival rates. This problem is made even more
pressing considering that minority patients are already at a disadvan-
tage with kidney transplant survival and gaining access to transplanta-
tion in the first place.81
The current Medicare policy did not intend to generate disparities
in medical outcomes by virtue of the insurance and income disparities
experienced by kidney recipients. Having equal access to transplanta-
tion, as the entitlement policy promises, should mean that all kidney
recipients would have sufficient Medicare or private insurance cover-
age to enable them to obtain the immunosuppressants that maintain
kidney graft survival, and that this coverage continues for the duration
of the life of the graft.
VI. IMPACT OF INSURANCE COVERAGE ON QUALITY OF LIFE
In addition to the survival of the kidney graft, it is also important to
consider how the financial challenge of procuring enough funds to ob-
tain immunosuppressants can demoralize kidney recipients and dra-
matically destabilize quality of life. Kidney transplantation has been
touted as providing a better QOL over dialysis. But some meta-analy-
ses question this proposition, given patients' adverse health problems
and difficulty in obtaining funds for medications.8 2
Various empirical studies support the relationship between insur-
ance coverage or financial support and QOL. Research shows that
having pharmacy insurance coverage has a positive effect on life satis-
79. Didlake et al., supra note 74; Rovelli et al., supra note 78.
80. Ross B. Isaacs et al., Racial Disparities in Renal Transplant Outcomes, 34 AM. J. KIDNEY
DISEASES 706 (1999).
81. G. Caleb Alexander & Ashwini R. Sehgal, Barriers to Cadaveric Renal Transplantation
Among Blacks, Women, and the Poor, 280 JAMA 1148 (1998).
82. Donald Joralemon & Kim Mika Fujinaga, Studying the Quality of Life After Organ Trans-
plantation: Research Problems and Solutions, 44 Soc. SCI. & MED. 1259 (1996).
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faction, a component of QOL.8 3 Another study of posttransplant
QOL also suggests that kidney recipients rate their QOL lower when
they are disadvantaged economically. 84 A QOL study examining the
impact of financial changes on kidney recipients' lives found that fi-
nancial concerns presented the greatest stress compared to any other
stressor after kidney transplantation. 85 In a qualitative investigation
of patients' experiences living with kidney transplantation, one re-
spondent reported the following devastating effects of transplant costs
on his family's life:
There are many days now when I wonder whether I should have
gone through with this. We've spent all our life savings, money that
was meant for our retirement and that we've saved to send my
daughter to college. We've lost all we had-our house, my wife's
new car, all our assets-to pay for my operation. When I look back
on it now I think it would be better if I was dead. Look what I've
done to the people who love me.86
Clearly, the financial strain that some kidney transplant recipients ex-
perience reduces their QOL and may very well negatively affect their
graft survival. In sum, the current Medicare policy can be construed
as a factor contributing to the decrease in kidney recipients' QOL,
even though it was designed to increase it. Basically, the Medicare
policy's limitations reinforce disparities in survival and QOL out-
comes. This contention is borne out in economic analyses of the pol-
icy, described below.
VII. COST CONSIDERATIONS: EFFICIENCY
The financial expenditures for the ESRD program are increasing
significantly as the ESRD patient population inexorably grows-espe-
cially among the elderly and those with many comorbidities who pre-
sent greater healthcare needs-and survival increases.8 7 Accordingly,
it is imperative to find ways to enhance cost efficiency for the ESRD
system. Whereas ESRD patients represent half of one percent of the
Medicare population, their care accounts for five percent of Medicare
expenditures. 88 In 1991, Medicare spending per beneficiary per year
83. Matas et a!., supra note 45.
84. C.T. Lazzaretti et al., Kidney Transplantation Improves the Multidimensional Quality of
Life, 36 TRANSPLANTATION PROC. 872 (2004).
85. Patricia A. Frazier et al., Stressors, Social Support, and Adjustment in Kidney Transplant
Recipients and Their Spouses, 21 Soc. WORK HEALTH CARE 93 (1995).
86. Sharp, supra note 63, at 374.
87. 2004 ANNUAL REPORT, supra note 15, at 65; Richard A. Rettig, The Social Contract and
the Treatment of Permanent Kidney Failure, 275 JAMA 1123 (1996).
88. Allen R. Nissenson & Richard A. Rettig, Medicare's End-Stage Renal Disease Program:
Current Status and Future Prospects, 18 HEALTH AFF. 161, 164 (1999).
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varied by age, ranging from $36,000 to $51,000.89 Kidney transplanta-
tion becomes more cost-effective than hemodialysis after 3.1 years.90
The cost of in-center hemodialysis is approximately $60,000 per mem-
ber per year (pmpy), whereas the cost of kidney transplantation for
functioning graft patients is approximately $15,357 pmpy in 2003. 91
Kidney transplantation can become even more cost-effective by im-
proving graft survival. A study from 1994, conducted at the time
when Medicare provided only one year of posttransplant immunosup-
pression coverage, estimated that the costs to Medicare during the
three years posttransplant were three times higher for patients who
experienced graft failure than for patients whose graft survived.92 The
United States Renal Data System study also estimated that the cost of
a return to dialysis due to kidney graft failure was approximately eight
times the cost of immunosuppressant drugs. This study played a piv-
otal role in prompting the law to extend the duration of immunosup-
pressant coverage to three years.93 A more recent study found that
the actual costs of posttransplant immunosuppression are lower than
dialysis costs. 94
Compelling evidence that extending Medicare policy improves graft
survival is found in one study that examined the extension of Medi-
care's immunosuppression coverage from one year in 1986 to three
years in 1995. 95 Using data from the USRDS and zip code median
data from the census, Robert Woodward and colleagues compared the
graft survival by income level of two cohorts of patients: those receiv-
ing transplants in 1992-1993 who had only one year of coverage (co-
hort 1) and those receiving transplants in 1995-1997 who had three
years of coverage (cohort 2). At one year posttransplant for both co-
89. Id.
90. Kasiske et al., supra note 44, at 2448. There has been a trend toward an earlier break-even
point. Earlier studies reported a break-even point at four years, and more recent small-scale
studies report 2.8 years. See Paul W. Eggers & Lawrence E. Kucken, Cost Issues in Transplanta-
tion, 74 SURGICAL CLINICS N. AM. 1259 (1994); Laupacis et al., supra note 14; Patricia R.
Loubeau et al., The Economics of Kidney Transplantation Versus Hemodialysis, 11 PROGRESSIVE
TRANSPLANTATION, 291 (2001).
91. U.S. RENAL DATA SYSTEM, 2005 ANNUAL DATA REPORT: MEDICARE COSTS OF ESRD
680 tbl.K11 (2005). The transplant pmpy costs represent an average of the costs for new and
ongoing kidney transplant recipients in 2003. The costs of the new patients are substantially
higher given the operation and physician fees, but these are averaged out by the greater propor-
tion of ongoing patients. The proportion of new to ongoing patients was not provided in the
USRDS 2004 report.
92. 1997 ANNUAL DATA REPORT, supra note 54.
93. Shih, supra note 46.
94. Zolt~n Kal6, Economic Aspects of Renal Transplantation, 35 TRANSPLANTATION PROC.
1223 (2003).
95. Woodward et al., supra note 13, at 69.
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horts (the last point at which Medicare provided immunosuppression
coverage), there was no difference in survival. 96 At the second and
third years posttransplant, however, low income was negatively associ-
ated with graft survival for cohort 1 (when Medicare was not provid-
ing coverage). 97 For example, for cohort 1, at three years, the low-
income group had a 3.9% lower three-year graft survival than the
high-income group (p = 0.004).98 In contrast, for cohort 2, the low-
income group had a 0.8% lower three-year graft survival than the
high-income group.99 Medicare's extended immunosuppression cov-
erage benefited low-income patients the most: those without extended
coverage had a risk ratio of 1.40 (p < 0.001), meaning that they had a
forty percent higher risk of graft loss than high-income patients (con-
trolling for other factors). 100 The 4.5% of grafts lost at year three
among low-income patients represents 354 grafts lost from cohort 1,
and 555 grafts lost from cohort 2. The benefits of extended coverage
were also experienced among the next to highest income group. This
study shows that extending coverage offsets the existing survival dif-
ferential between recipients' socioeconomic backgrounds by affecting
patients' capacity to purchase immunosuppressant medications.
An even more recent study set out to estimate the expected eco-
nomic and clinical effects of extending Medicare immunosuppression
coverage from three years to the full life of the kidney graft (in 2000
dollars). 10' The study found that lifetime immunosuppressant cover-
age would have both outcome benefits and cost benefits.
Regarding outcome benefits, lifetime immunosuppression coverage
would reduce graft failure in the fourth year posttransplant from 4.4%
to 3.2% annually.10 2 One patient in nine would have a functioning
transplant graft for twenty years (which would have otherwise failed
without extended coverage). 0 3 The median projected patient survival
would increase to 27.8 years, compared to 24.4 years without lifetime
96. ROBERT H. BLANK & VIOLA BURAU, COMPARATIVE HEALTH POLICY: AN INTRODUC-
TION 1-28 (2004).
97. Id.
98. Id.
99. Id.
100. Id.
101. Eugene F. Yen et al., Cost-Effectiveness of Extending Medicare Coverage of lmmunosup-
pressive Medications to the Life of a Kidney Transplant, 4 AM. J. TRANSPLANTATION 1703 (2004).
The estimates were based on a twenty-seven percent relative reduction in kidney graft loss in
patients without alternative immunosuppression coverage as reported by Woodward. See Wood-
ward et al., supra note 13, at 72.
102. Id.
103. Id.
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coverage. 10 4 In other words, one patient in thirteen, who would have
otherwise died earlier, would be alive twenty years later.
Regarding costs, the annualized expected savings to society from
lifetime coverage would be $136 million (based on current rates of
transplantation). 10 5 The expected discounted costs to Medicare after
twenty years posttransplant would differ according to coverage level:
$234,894 with existing coverage and $268,946 with extended
coverage. 106
A comparative health policy perspective helps to illuminate how
policy is affected by cultural factors, reveal other policy options avail-
able, and highlights the differential impact of policies on health. 10 7
One comparative study of healthcare systems and kidney transplant
outcomes found that industrialized nations differ in the percentage of
patients with functioning renal transplants according to the kind of
healthcare system: public or "Beveridge" Model (e.g., Canada, United
Kingdom, Sweden); mixed or "Bismarck" Model (e.g., Germany, It-
aly, France); and private or "Private Insurance" Model (e.g., the
United States, Japan). 10 8 Public countries have the greatest percent-
age of patients with functioning renal transplants, ranging from forty-
five percent to eighty-one percent; mixed countries range from twenty
percent to forty-eight percent; and as a private country, the United
States has twenty-six percent (Japan has a rate of 0.3% due to cultural
and religious considerations).' 0 9 These data suggest that health policy
plays a critical role in kidney transplant survival. More importantly,
the United States should learn from these other policy models that in
order to increase the proportion of functioning renal transplants, a
greater level of financial support for such patients is imperative.
By these tokens, extending coverage of immunosuppression can
help prevent premature kidney rejection (due to insufficient funds to
purchase antirejection medications) and thereby limit the number of
patients who would return to the waiting list for retransplantation.
Improving transplantation survival is therefore imperative as a means
of keeping Medicare costs down.
104. Id.
105. Id.
106. Id.
107. BLANK & BURAU, supra note 96, at 1-28.
108. W. H. H6rI et al., Healthcare Systems and End-Stage Renal Disease (ESRD) Therapies-
An International Review: Access to ESRD Treatments, 14 NEPHROLOGY DIALYSIS & TRANS-
PLANrTATION 10, 10 (1999).
109. Id.
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VIII. CONCLUSION
This Article makes three key points. First and foremost, expanding
Medicare coverage for the life of the kidney is necessary. The current
Medicare policy limiting immunosuppressive medication coverage to
eighty percent for three years undermines the goals of increasing graft
survival and enhancing the quality of life for kidney transplant recipi-
ents that the policy initially set out to address. This is particularly the
case among the most financially needy patients. The policy is also
more costly than providing longer-term coverage.
The second key point is that efforts to increase equity in the kidney
transplant endeavor must encompass issues of equity in graft survival
outcomes. Considerations of justice in terms of equity pervade the
transplant effort, notably in efforts to foster equitable access to and
allocation of kidney transplants.110 But attention to equity in kidney
transplantation has been limited to the stages leading up to the receipt
of the transplant, neglecting policies relating to posttransplant sur-
vival. As one commentator noted, "The ultimate test of the equity of
a health policy is the extent to which disparities or inequities in health
persist among subgroups of the population."11' Yet, as I have shown
above, the current Medicare policy fosters social and economic dispar-
ities in transplant survival outcomes given limited Medicare coverage
and disparities in insurance coverage. Therefore, to foster greater eq-
uity in outcomes, we must address questions of disparities in access to
immunosuppression.
The third point has to do with revising our framework or vision for
kidney transplantation and for addressing the first two points. The
spectrum of our efforts in the kidney transplant endeavor has tradi-
tionally spanned from the stages of identifying patients in need of or-
gans to the process of facilitating a safe transplant operation. As
policymakers at the Centers for Medicare and Medicaid Services
stated, "Increasing the supply of kidneys and other organs for trans-
plantation is a priority initiative of the Secretary of the Department of
Health and Human Services." 112 I posit, however, that the spectrum
of attention transplant professionals, scholars, and policymakers
110. See, e.g., G. Caleb Alexander & Ashwini R. Sehgal, Why Hemodialysis Patients Fail to
Complete the Transplantation Process, 37 AM. J. KIDNEY DISEASES 321 (2001); Christopher F.
Bryan et al., HLA Points Assigned in Cadaveric Kidney Allocation Should Be Revisited: An
Analysis of HLA Class II Molecularly Typed Patients and Donors, 3 AM. J. TRANSPLANTATION
459 (2003).
111. Lu Ann Aday et al., A Framework for Assessing the Effectiveness, Efficiency, and Equity
of Behavioral Healthcare, 5 AM. J. MANAGED CARE SP25, SP41 (1999).
112. Joel W. Greer, End Stage Renal Disease and Medicare, 24 HEALTH CARE FIN. REV. 1, 4
(2003) (emphasis added).
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devote to transplant efforts should be extended beyond the point of
receiving an organ transplant to the period of rehabilitation and main-
tenance of life with a transplant more than the current situation of
three years. I also propose that we may have been placing dispropor-
tionate attention on one end of the spectrum (i.e., efforts to increase
donation) to the neglect of the other end-transplant graft survival.
These proposals together suggest that we must reconceptualize our
end goal not just as transplantation, but also as long-term transplant
survival. This framework is extremely important in order to make the
transplant endeavor worthwhile for patients, donors, and society for
improvement in health, quality of life, the availability of kidney grafts,
and financial investment.
Accordingly, an expanded notion of "access to transplantation" is
necessary given that attainment of a kidney transplant becomes moot
if the social structural supports for maintaining a transplant are un-
available to patients. That is, in order for a kidney transplant to work
in the first place, kidney recipients must have the resources to obtain
immunosuppression for the life of the kidney. A broader notion of
access to transplantation would therefore consider access to a surviv-
ing transplant through available immunosuppressants. Expanding the
notion of access would foster greater parity in transplant survival and
enable an ethical analysis of disparities in long-term transplant out-
comes. Yet, even with these resources and complete access to immu-
nosuppression, there may still be differences in survival by
socioeconomic status. Such access, however, will narrow the gap
considerably.
As some kidney transplant professionals acknowledge, a long-term
approach to kidney transplant survival is necessary. Toward this end,
transplant professionals have called for efforts to prevent and treat
cardiovascular disease, infection, bone disease, neoplasia, and chronic
allograft nephropathy. 113 Other scholars have called for tailored ther-
apies to individual patients; they recommend identifying patient seg-
ments that most clearly benefit from the most expensive
immunosuppressive regimens to justify use." 4 Still other scholars
have argued for increased use of generics to enable patients to afford
immunosuppressive medications. 115 Pharmacoeconomic research is
striving to ascertain the cost-effectiveness of various immunosuppres-
113. See, e.g., Magee & Pascual, supra note 8.
114. Gorman, supra note 10; Kal6, supra note 94.
115. S. A. A. Naqvi, Immunosuppression Strategies in Developing Countries, 34 TRANSPLAN-
TATION PROC. 2083 (2002); Vinay Sakhuja & Kamal Sud, End-Stage Renal Disease in India and
Pakistan: Burden of Disease and Management Issues, 63 KIDNEY INT'L S-115, S-117 (2003).
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sion regimens, thereby helping to reduce costs of medications to pa-
tients.116 These clinical approaches to improving long-term outcomes
are necessary, but insufficient. Rather, it is imperative that we be-
come cognizant of the broader political, economic, social, and cultural
contexts in which patients live with and manage their kidney trans-
plants in the long-term.
Medicare policy must shift in concert with the needs of the kidney
recipient population and the advances in medical technology that en-
able long-term survival in the first place. Currently, the policy can
present challenges to graft survival and quality of life because of the
financial hardship it presents to patients without the economic support
to obtain immunosuppression. Expanding Medicare coverage for the
life of the kidney is necessary. Moreover, the proposed extension of
Medicare coverage of immunosuppression is defensible in light of the
increasing emphasis that ESRD policymakers are placing on quality
improvement strategies to improve ESRD patients' functional status
and outcomes. 117
Granted, a long-term approach is not exciting. Medicine has tradi-
tionally focused on acute care issues to the neglect of chronic care.
Similarly, policymakers and researchers tend to focus on the short-
term outcomes rather than long-term outcomes to receive the acclaim
of definitive gains. These factors, however, do not preclude the pro-
posed policy change. Expanding Medicare coverage would fall
squarely within the trajectory of progressively increasing coverage
provided by Medicare over time. As such, this proposal would not
come out of place. Rather, this policy change would make the trans-
plant endeavor all the more worthwhile.
This Article has presented the ethical grounds for the need to pro-
vide long-term healthcare coverage for immunosuppression. A corre-
sponding argument on economic grounds requires a cost-benefit
analysis of this proposal. To date, few analyses have been conducted.
An effective argument for providing extended coverage should con-
sider several variables, including: (1) the cost of QOL for patients with
and without the financial wherewithal to purchase immunosuppres-
sants, (2) the actual costs of extending coverage beyond three years
versus the costs of dialysis, (3) graft survival statistics between adher-
ent patients with immunosuppressants versus nonadherent patients
116. See, e.g., Michelle E. Orme et al., The Cost Effectiveness of Tacrolimus Versus
Microemulsified Cyclosporin: A 10-Year Model of Renal Transplantation Outcomes, 21
PHARMACOECONOMICS 1263 (2003).
117. See Nissenson & Rettig, supra note 88.
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due to financial strain after three years posttransplant,"1 8 and (4) the
number of patients waiting for second and third kidney transplants
(due to graft loss from financial strain). In order to make a convincing
policy argument, these economic analyses are needed.
Moreover, greater advocacy for policy change by transplant profes-
sionals, nephrologists, and pharmaceutical companies is needed, espe-
cially now that Congress is currently reviewing proposed legislation to
extend Medicare coverage of immunosuppressants. It may be the case
that health professionals are not necessarily focused on this issue
given their distraction with ensuring appropriate reimbursement rates
for patient care from Medicare.11 9 With ethical and economic analy-
ses and advocacy, we can change health policy for the betterment and
equity of kidney transplant outcomes.
118. See, e.g., Irina Cleemput et al., The Economic Implications of Non-Adherence After Renal
Transplantation, 22 PHARMACOECONOMICS 1217 (2004). Because this study was conducted in
Belgium and analyses performed one-year posttransplant, the impact of the U.S. Medicare pol-
icy on nonadherence due to the financial strain caused by Medicare coverage termination could
not be assessed.
119. The Coalition of the Kidney Care Partners has been lobbying for increasing the compos-
ite rates of reimbursement. This is a longstanding, controversial issue. See Richard A. Rettig &
Ellen L. Marks, Implementing the End-Stage Renal Disease Program of Medicare (Rand Corp.,
Inst. For Civil Justice No. R-2505-HCFA/HEW, 1980).
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